NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?
![NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?](https://www.ohe.org/wp-content/uploads/2023/09/andrew-butler-aUu8tZFNgfM-unsplash-scaled.jpg)
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.